RBC Capital Maintains Sector Perform on Chemours, Raises Price Target to $36
RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Sector Perform and raises the price target from $33 to $36.
Credit Suisse Maintains Underperform on Chemours, Raises Price Target to $27
Credit Suisse analyst John Roberts maintains Chemours (NYSE:CC) with a Underperform and raises the price target from $24 to $27.
Chemours Q4 Sales $1.34B Beat $1.27B Estimate
Chemours (NYSE:CC) reported quarterly sales of $1.34 billion which beat the analyst consensus estimate of $1.27 billion by 5.35 percent. This is a 15.05 percent decrease over sales of $1.57 billion the same period last
Earnings Scheduled For February 9, 2023
Companies Reporting Before The Bell
• AstraZeneca (NASDAQ:AZN) is expected to report quarterly earnings at $0.67 per share on revenue of $11.21 billion.
5 Value Stocks To Watch In The Basic Materials Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace…
Benzinga’s Top Ratings Upgrades, Downgrades For January 10, 2023
Upgrades Morgan Stanley upgraded the previous rating for Stem Inc (NYSE:STEM) from Equal-Weight to Overweight. In the third…
RBC Capital Downgrades Chemours to Sector Perform, Lowers Price Target to $33
RBC Capital analyst Arun Viswanathan downgrades Chemours (NYSE:CC) from Outperform to Sector Perform and lowers the price target from $35 to $33.
Chemours Q3 Adj. EPS $1.24 Beats $1.07 Estimate, Sales $1.78B Beat $1.68B Estimate
Chemours (NYSE:CC) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.07 by 15.89 percent. This is a 2.36 percent decrease over earnings of $1.27 per share from the same period
Morgan Stanley Maintains Equal-Weight on Chemours, Lowers Price Target to $33
Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $41 to $33.
Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $30
Barclays analyst Michael Leithead maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $46 to $30.